Literature DB >> 33414961

Examination and Comparison of Cognitive and Executive Functions in Clinically Stable Schizophrenia Disorder, Bipolar Disorder, and Major Depressive Disorder.

Behrooz Afshari1, Nasrin Shiri1, Fatemeh Sadat Ghoreishi1, Mohtasham Valianpour2.   

Abstract

BACKGROUND: Schizophrenia (SC), bipolar disorder (BD), and major depressive disorder (MDD) are associated with various cognitive and executive dysfunctions. The aim of the present study was to evaluate and compare cognitive and executive dysfunctions in schizophrenia, bipolar disorder, and major depressive disorder.
MATERIALS AND METHODS: Sixty-four schizophrenia patients, 68 bipolar patients, 62 patients with major depressive disorder, and 75 healthy individuals participated in the present study. All participants were assessed with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Young Mania Rating Scale (YMRS), Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI-II), Trial Making Test (TMT), Four-Choice Reaction Time Task, Ruler Drop Method (RDM), Tower of London (TOL) task, and the Wisconsin Card Sorting Task (WCST). Data were analyzed by chi-square, Kolmogorov-Smirnov, and independent t-tests; ANOVA; and MANOVA.
RESULTS: In the cognitive function, the scores of SC, BD, and MDD patients were lower than those of healthy individuals. Also, the scores of MDD patients were lower than those of other patients, and the scores of BD patients were lower than those of SC patients. In the executive function, the scores of SC, BD, and MDD patients were lower than those of healthy individuals. Moreover, the scores of the MDD group were higher than those of the BD and SC groups, and the scores of the SC group were higher than those of the BD group.
CONCLUSION: Patients with SC, BD, and MDD have poorer cognitive and executive functions than healthy individuals, even when these patients are in a stable state. Assessment of cognitive and executive functions in SC, BD, and MDD patients can help in understanding the pathology of these disorders.
Copyright © 2020 Behrooz Afshari et al.

Entities:  

Year:  2020        PMID: 33414961      PMCID: PMC7752301          DOI: 10.1155/2020/2543541

Source DB:  PubMed          Journal:  Depress Res Treat        ISSN: 2090-1321


  53 in total

1.  A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits.

Authors:  Julie D Henry; John R Crawford
Journal:  Cogn Neuropsychiatry       Date:  2005-01       Impact factor: 1.871

2.  Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships?

Authors:  Margaret M McClure; Christopher R Bowie; Thomas L Patterson; Robert K Heaton; Christine Weaver; Hannah Anderson; Philip D Harvey
Journal:  Schizophr Res       Date:  2006-09-18       Impact factor: 4.939

3.  Cognitive functioning in patients with affective disorders and schizophrenia: a meta-analysis.

Authors:  Evgenia Stefanopoulou; Andiappan Manoharan; Sabine Landau; John R Geddes; Guy Goodwin; Sophia Frangou
Journal:  Int Rev Psychiatry       Date:  2009

4.  [Spanish version of a scale for the assessment of mania: validity and reliability of the Young Mania Rating Scale].

Authors:  Francesc Colom; Eduard Vieta; Anabel Martínez-Arán; Margarida Garcia-Garcia; María Reinares; Carla Torrent; José Manuel Goikolea; Sebastià Banús; Manel Salamero
Journal:  Med Clin (Barc)       Date:  2002-09-28       Impact factor: 1.725

5.  Effect of symptoms on executive function in bipolar illness.

Authors:  T Dixon; E Kravariti; C Frith; R M Murray; P K McGuire
Journal:  Psychol Med       Date:  2004-07       Impact factor: 7.723

Review 6.  Neuroprogression in bipolar disorder.

Authors:  Marguerite Reid Schneider; Melissa P DelBello; Robert K McNamara; Stephen M Strakowski; Caleb M Adler
Journal:  Bipolar Disord       Date:  2012-06       Impact factor: 6.744

7.  The association of duration and severity of disease with executive function: Differences between drug-naïve patients with bipolar and unipolar depression.

Authors:  Tao Yang; Guoqing Zhao; Ruizhi Mao; Jia Huang; Xianrong Xu; Yousong Su; Na Zhu; Rubai Zhou; Xiao Lin; Weiping Xia; Fan Wang; Rui Liu; Xing Wang; Zhijia Huang; Yong Wang; Yingyan Hu; Lan Cao; Chengmei Yuan; Zuowei Wang; Raymond W Lam; Jun Chen; Yiru Fang
Journal:  J Affect Disord       Date:  2018-05-29       Impact factor: 4.839

8.  Executive function impairments in depression and bipolar disorder: association with functional impairment and quality of life.

Authors:  Charles Cotrena; Laura Damiani Branco; Flávio Milman Shansis; Rochele Paz Fonseca
Journal:  J Affect Disord       Date:  2015-11-12       Impact factor: 4.839

Review 9.  Measuring cognitive function in MDD: emerging assessment tools.

Authors:  Manuela Russo; Katie Mahon; Katherine E Burdick
Journal:  Depress Anxiety       Date:  2014-11-24       Impact factor: 6.505

Review 10.  Cognitive impairment in depression: recent advances and novel treatments.

Authors:  Giulia Perini; Matteo Cotta Ramusino; Elena Sinforiani; Sara Bernini; Roberto Petrachi; Alfredo Costa
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.